scispace - formally typeset
J

Julie Lonjon

Publications -  2
Citations -  540

Julie Lonjon is an academic researcher. The author has contributed to research in topics: Sorafenib & Tare weight. The author has an hindex of 1, co-authored 2 publications receiving 384 citations.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, +111 more
- 01 Dec 2017 - 
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI

Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.

Kevin Zarca, +106 more
TL;DR: In this article, the authors performed a cost-utility analysis of transarterial radioembolization (TARE) versus oral sorafenib for hepatocellular carcinoma.